PL326714A1 - Novel macrocyclic compounds as inhibitors of metaloproteinases - Google Patents

Novel macrocyclic compounds as inhibitors of metaloproteinases

Info

Publication number
PL326714A1
PL326714A1 PL96326714A PL32671496A PL326714A1 PL 326714 A1 PL326714 A1 PL 326714A1 PL 96326714 A PL96326714 A PL 96326714A PL 32671496 A PL32671496 A PL 32671496A PL 326714 A1 PL326714 A1 PL 326714A1
Authority
PL
Poland
Prior art keywords
metaloproteinases
inhibitors
macrocyclic compounds
novel macrocyclic
novel
Prior art date
Application number
PL96326714A
Other languages
English (en)
Inventor
Chu-Biao Xue
Robert Joseph Cherney
Carl Peter Decicco
William Frank Degrado
Xiaohua He
Carl Nicolas Hodge
Irina Cipora Jacobson
Ronald Louis Magolda
Elizabeth Catherine Arner
Jingwu Duan
David J Nelson
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of PL326714A1 publication Critical patent/PL326714A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL96326714A 1995-11-14 1996-11-13 Novel macrocyclic compounds as inhibitors of metaloproteinases PL326714A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US668495P 1995-11-14 1995-11-14
US64690296A 1996-05-08 1996-05-08
US74343996A 1996-11-01 1996-11-01

Publications (1)

Publication Number Publication Date
PL326714A1 true PL326714A1 (en) 1998-10-26

Family

ID=27358171

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96326714A PL326714A1 (en) 1995-11-14 1996-11-13 Novel macrocyclic compounds as inhibitors of metaloproteinases

Country Status (17)

Country Link
EP (1) EP0863885A2 (fr)
JP (1) JP2000502050A (fr)
CN (1) CN1202161A (fr)
BR (1) BR9611563A (fr)
CA (1) CA2237524A1 (fr)
CZ (1) CZ144798A3 (fr)
EE (1) EE9800115A (fr)
HR (1) HRP960533A2 (fr)
HU (1) HUP0201479A2 (fr)
IL (1) IL124366A0 (fr)
LV (1) LV12167B (fr)
MX (1) MX9803851A (fr)
NO (1) NO982185L (fr)
PL (1) PL326714A1 (fr)
SI (1) SI9620120A (fr)
SK (1) SK63498A3 (fr)
WO (1) WO1997018207A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
ZA9820B (en) * 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
BR9909420A (pt) 1998-03-31 2001-09-25 Du Pont Pharm Co Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
CA2333551A1 (fr) 1998-06-11 1999-12-16 Zhe Wang Procede de preparation d'inhibiteurs macrocycliques des metalloproteases
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (fr) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005044780A1 (fr) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p
CA2708281A1 (fr) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Inhibiteurs de metalloenzymes utilisant des fractions de liaison a un metal en combinaison avec des fractions de ciblage
WO2009099174A1 (fr) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
WO2010132494A1 (fr) * 2009-05-11 2010-11-18 Ghosh Arun K Composés et méthodes utilisables dans le cadre du traitement du sida et des infections par le vih
EP2710018B8 (fr) 2011-05-19 2022-02-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Composés macrocycliques en tant qu'inhibiteurs des protein kinases
CN102276546B (zh) * 2011-05-31 2014-06-25 中国科学院广州生物医药与健康研究院 用作蛋白聚糖酶调节剂的化合物及其应用
CN108727293B (zh) * 2016-09-18 2021-05-11 广西师范大学 1，2，8-氧代二氮杂环壬-9-酮衍生物及其合成方法
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis

Also Published As

Publication number Publication date
EP0863885A2 (fr) 1998-09-16
CA2237524A1 (fr) 1997-05-22
LV12167B (en) 1999-03-20
SI9620120A (sl) 1999-06-30
EE9800115A (et) 1998-10-15
NO982185L (no) 1998-07-13
JP2000502050A (ja) 2000-02-22
HRP960533A2 (en) 1998-04-30
WO1997018207A3 (fr) 1997-07-24
SK63498A3 (en) 1999-01-11
CN1202161A (zh) 1998-12-16
HUP0201479A2 (en) 2002-08-28
NO982185D0 (no) 1998-05-13
IL124366A0 (en) 1998-12-06
MX9803851A (es) 1998-09-30
LV12167A (lv) 1998-11-20
BR9611563A (pt) 1999-03-02
CZ144798A3 (cs) 1998-10-14
WO1997018207A2 (fr) 1997-05-22

Similar Documents

Publication Publication Date Title
PL326714A1 (en) Novel macrocyclic compounds as inhibitors of metaloproteinases
PL339738A1 (en) Novel lactamic inhibitors of metaloproteinases
PL327569A1 (en) Promedications of thrombosin inhibitors
GB2308366B (en) Tri-substituted phenyl derivatives useful as PDE IV inhibitors
PL321759A1 (en) Novel thrombosin inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
PL327998A1 (en) Novel derivatives of 19-nor-pregnene
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
EP0833630A4 (fr) Nouveaux composes de benzopyranne et leurs procedes d'utilisation
AU2438297A (en) Combinations of angiostatic compounds
PL331920A1 (en) Spirocyclic inhibitors of metaloproteases
PL322722A1 (en) Novel heterocyclic compounds
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
PL324034A1 (en) Tribenzimidazoles useful as inhibitors of topoisomerase i
PL325122A1 (en) Bicyclic derivatives of 4-aralkylamino pyrididine as inhibitors of thyrosinic kinase
AU2277597A (en) New inhibitors of sh2-mediated processes
AU4337497A (en) Tricyclic compounds useful as fpt inhibitors
AU5271096A (en) Novel heterocyclic compounds
AU2033497A (en) Articles of jewellery
IL113228A (en) Derivatives of anandamide
AU4633397A (en) Synthesis of phosphorus compounds
PL325637A1 (en) Novel heterocyclic compounds
AU5270896A (en) Novel heterocyclic compounds
LT95119A (en) Composition of whisky
ZA963825B (en) Composition of matter